<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966875</url>
  </required_header>
  <id_info>
    <org_study_id>12061</org_study_id>
    <secondary_id>I1F-MC-RHAK</secondary_id>
    <nct_id>NCT00966875</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to help answer the following research questions, and not
      to provide treatment for Rheumatoid Arthritis (RA):

        -  The safety of LY2439821 and any side effects that might be associated with it.

        -  Whether LY2439821 can help participants with active RA.

        -  How much LY2439821 should be given to participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study I1F-MC-RHAK is a multicenter study in participants with active RA on concomitant
      conventional DMARD therapy. The study is a Phase 2 study with 2 parts. Part A is a
      randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design and Part B
      is an optional, open-label extension design. Two participant populations will be evaluated in
      this study: bDMARD-naive participants and TNFα-IR participants. Participants in Part A
      receive multiple subcutaneous injections of LY2439821 [bDMARD-naive participants: 0
      (placebo), 3, 10, 30, 80, or 180 mg; TNFα-IR participants: 0 (placebo), 80 or 180 mg] at
      Weeks 0, 1, 2, 4, 6, 8, and 10. Participants in Part B receive subcutaneous injections of
      LY2439821 160 mg at Weeks 16, 18, and 20, and every 4 weeks thereafter through Week 60.
      Participants who complete both Part A and B have a total study participation of up to
      approximately 72 to 84 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population</measure>
    <time_frame>Week 12</time_frame>
    <description>DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 − CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score (DAS28)-Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ACR20/50/70 Response - Part A</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With of ACR20/50/70 Response - Part B</measure>
    <time_frame>Week 64</time_frame>
    <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain.&quot; The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain&quot;. The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A</measure>
    <time_frame>Week 12</time_frame>
    <description>Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in EULAR28 - Part B</measure>
    <time_frame>Week 64</time_frame>
    <description>Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR-N - Part A</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value) / baseline value] * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR-N - Part B</measure>
    <time_frame>Week 64</time_frame>
    <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value)/baseline value] * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACIT Fatigue Scale - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI - Part A</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
    <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI - Part B</measure>
    <time_frame>Baseline, Week 64</time_frame>
    <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Exposure and Response of Individual Components of the ACR Core Set</measure>
    <time_frame>Through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Exposure and Response of ACR20/50/70/N</measure>
    <time_frame>Through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Exposure and Response of DAS28</measure>
    <time_frame>Through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Exposure and Response of EULAR28</measure>
    <time_frame>Through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State</measure>
    <time_frame>Predose: Day 0, Day 1 or 2 or 3, Day 7, Weeks 6, 10, 16, 40 and 64 and Postdose: Day 0 and Week 6</time_frame>
    <description>Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-LY2439821 Antibodies</measure>
    <time_frame>Week 16, Week 64</time_frame>
    <description>Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>3 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg LY2439821 (TNFa-IR population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg LY2439821 (TNFa-IR population)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (bDMARD-naive population)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (TNFa-IR population)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY2439821</intervention_name>
    <description>Subcutaneous</description>
    <arm_group_label>3 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_label>10 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_label>30 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_label>80 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_label>180 mg LY2439821 (bDMARD-naive population)</arm_group_label>
    <arm_group_label>80 mg LY2439821 (TNFa-IR population)</arm_group_label>
    <arm_group_label>180 mg LY2439821 (TNFa-IR population)</arm_group_label>
    <other_name>ixekizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous</description>
    <arm_group_label>Placebo (bDMARD-naive population)</arm_group_label>
    <arm_group_label>Placebo (TNFa-IR population)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must be between the ages of 18 and 75

          -  You must have active RA

        Qualifications Specific to the bDMARD-naive Population:

        You must be regularly using methotrexate (MTX) for at least 12 weeks before your
        participation in this study

        Qualifications Specific to the TNFα-IR Population:

          -  You must have been treated with at least 1 biologic TNFα inhibitor therapy and either
             had an insufficient response to at least 3 months of treatment OR have been intolerant
             of such treatment

          -  You must be regularly using at least 1 conventional DMARD in a stable treatment
             regimen

        Exclusion Criteria:

          -  You are concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless you
             are on a stable dose within the last 2 weeks

          -  You are a woman who is lactating or breast feeding

          -  You have donated more than 300 milliliters (mL) of blood within the last month

          -  You have received glucocorticoid administered by intra-articular, intramuscular, or
             intravenous injection or oral corticosteroids at an average daily dose of greater than
             10 mg per day of prednisone or its equivalent within the last 4 weeks

          -  You had surgery on a joint that is to be assessed in the study within 2 months of
             study enrollment, or will require such during the study

          -  You have another serious disorder or illness

          -  You suffered a serious bacterial infection (for example, pneumonia, cellulitis, or
             bone or joint infections) within the last 3 months

          -  You have a history of uncontrolled high blood pressure

          -  You have clinical laboratory test results at entry that are outside the normal
             reference range

          -  You are an employee of the clinic or you are an immediate family member of an employee
             of the clinic. Immediate family member is defined as a spouse, parent, child, or
             sibling, whether biological or legally adopted

          -  You are currently participating in or were discontinued within the last 30 days from
             another clinical trial involving an investigational drug

          -  If you are a woman and you could become pregnant during this study, you must talk to
             the study doctor about the birth control that you will use to avoid getting pregnant
             during the study.

          -  If you are a post-menopausal woman, you must be at least 45 years of age and have not
             menstruated for the last 12 months

          -  If you are a post-menopausal woman between 40 and 45 years of age, test negative for
             pregnancy, and have not menstruated during the last 12 months only, you must have an
             additional blood test to see if you can participate.

          -  If you are male, you must agree to reduce the risk of your female partner becoming
             pregnant during the study.

        Exclusions Specific to the bDMARD-naive Population:

          -  You have received any prior bDMARD therapy such as TNFα, Interleukin (IL)-1, IL-6,
             T-cell, or B-cell targeted therapies

          -  You have had an inadequate response to a minimum of 3 months of treatment with 5 or
             more conventional DMARDs [such as leflunomide, azathioprine, cyclosporine, etcetera
             (etc.)]

          -  You have used DMARDs other than MTX, hydroxychloroquine, or sulfasalazine within the
             last 8 weeks

          -  You have used leflunomide within the last 12 weeks and have not received
             cholestyramine to speed up the elimination of leflunomide from your body.

        Exclusions Specific to the TNFα-IR Population:

          -  You are currently using or recently used a bDMARD or a biologic TNFα inhibitor therapy
             within specified periods

          -  You have had a serious reaction to other biologic DMARDs that, in the study doctor's
             opinion, puts you at serious risk

          -  You have used cyclosporine or any other immunosuppressive in the 8 weeks before your
             participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>05400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hohenfelde</city>
        <zip>18209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tubingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>560079</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jaipur</city>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Secunderabad</city>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daejeon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pueblo Libre</city>
        <zip>Lima 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baia Mare</city>
        <zip>430110</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>10584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung County</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <disposition_first_submitted>August 9, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to Part A and had the option of continuing in the open-label extension, Part B after completing Part A.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo [bDMARD-naive Population]</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 milligrams (mg) LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]</description>
        </group>
        <group group_id="P2">
          <title>3 mg LY2439821 [bDMARD-naive Population]</title>
          <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P3">
          <title>10 mg LY2439821 [bDMARD-naive Population]</title>
          <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P4">
          <title>30 mg LY2439821 [bDMARD-naive Population]</title>
          <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P5">
          <title>80 mg LY2439821 [bDMARD-naive Population]</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P6">
          <title>180 mg LY2439821[bDMARD-naive Population]</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P7">
          <title>Placebo [TNFα-IR Population]</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]</description>
        </group>
        <group group_id="P8">
          <title>80 mg LY2439821 [TNFα-IR Population]</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="P9">
          <title>180 mg LY2439821 [TNFα-IR Population]</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="64"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received ≥1 Doses of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="64"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="58"/>
                <participants group_id="P9" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46">Two (2) participants who completed Part A did not enter Part B.</participants>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="51">One (1) participant who completed Part A did not enter Part B.</participants>
                <participants group_id="P6" count="32">One (1) participant who completed Part A did not enter Part B.</participants>
                <participants group_id="P7" count="51">One (1) participant who completed Part A did not enter Part B.</participants>
                <participants group_id="P8" count="57">One (1) participant who completed Part A did not enter Part B.</participants>
                <participants group_id="P9" count="50">One (1) participant who completed Part A did not enter Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="19"/>
                <participants group_id="P9" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo [bDMARD-naive Population]</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B2">
          <title>3 mg LY2439821 [bDMARD-naive Population]</title>
          <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B3">
          <title>10 mg LY2439821 [bDMARD-naive Population]</title>
          <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B4">
          <title>30 mg LY2439821 [bDMARD-naive Population</title>
          <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B5">
          <title>80 mg LY2439821 [bDMARD-naive Population]</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B6">
          <title>180 mg LY2439821[bDMARD-naive Population]</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B7">
          <title>Placebo [TNFα-IR Population]</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B8">
          <title>80 mg LY2439821 [TNFα-IR Population]</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B9">
          <title>180 mg LY2439821 [TNFα-IR Population]</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="57"/>
            <count group_id="B6" value="37"/>
            <count group_id="B7" value="64"/>
            <count group_id="B8" value="65"/>
            <count group_id="B9" value="59"/>
            <count group_id="B10" value="448"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="55"/>
                    <measurement group_id="B9" value="52"/>
                    <measurement group_id="B10" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.99" spread="10.18"/>
                    <measurement group_id="B2" value="52.19" spread="9.67"/>
                    <measurement group_id="B3" value="53.86" spread="10.62"/>
                    <measurement group_id="B4" value="53.03" spread="12.16"/>
                    <measurement group_id="B5" value="52.60" spread="10.91"/>
                    <measurement group_id="B6" value="52.21" spread="11.33"/>
                    <measurement group_id="B7" value="53.19" spread="10.44"/>
                    <measurement group_id="B8" value="54.74" spread="11.12"/>
                    <measurement group_id="B9" value="52.43" spread="9.90"/>
                    <measurement group_id="B10" value="53.08" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="55"/>
                    <measurement group_id="B8" value="57"/>
                    <measurement group_id="B9" value="51"/>
                    <measurement group_id="B10" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="48"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="43"/>
                    <measurement group_id="B10" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="54"/>
                    <measurement group_id="B8" value="58"/>
                    <measurement group_id="B9" value="50"/>
                    <measurement group_id="B10" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="31"/>
                    <measurement group_id="B10" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population</title>
        <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient’s Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient’s Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician’s Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population</title>
          <description>ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient’s Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient’s Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician’s Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="52.2"/>
                    <measurement group_id="O4" value="55.0"/>
                    <measurement group_id="O5" value="55.3"/>
                    <measurement group_id="O6" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>A log transformed dose was used in the model.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population</title>
        <description>ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were TNFα-IR.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ACR20 Response in Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR) Population</title>
          <description>ACR20 responders were participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) * 100.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were TNFα-IR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population</title>
        <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg to 180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg to 180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR 20 Response in bDMARD-Naive Population</title>
          <description>ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. The model used in the dose response analysis was used to estimate the doses that achieved 10%, 50%, and 90% of the maximal drug efficacy. Missing values were imputed using NRI. The log transformed dose was evaluated.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
          <units>log (dose) mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Estimated dose to achieve 10% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 50% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 90% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population</title>
        <description>DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 − CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg to 180 mg (bDMARD-naive Population)</title>
            <description>3 mg to 180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Smallest Doses That Achieved 10%, 50%, and 90% of the Maximum Disease Activity Score (DAS) 28 Response in bDMARD-Naive Population</title>
          <description>DAS modified included the 28 diarthrodial joint count (DAS28) that consisted of a composite score of the following variables: TJC out of 28 (TJC28), SJC out of 28 (SJC28), CRP [milligrams per liter (mg/L)], and PtGADA on a 0 to 100 millimeter (mm) VAS ranging from 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 was calculated as: DAS28 − CRP = 0.56(square root of TJC28) + 0.28(square root of SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
          <units>log (dose) mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Estimated dose to achieve 10% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 50 % response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 90% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population</title>
        <description>ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg to 180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg to 180 mg LY2439821administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Smallest Doses That Achieve 10%, 50%, and 90% of the Maximum ACR50 Response in bDMARD-Naive Population</title>
          <description>ACR50 responders were participants with at least 50% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug and were bDMARD-naive.</population>
          <units>log (dose) mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Estimated dose to achieve 10% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 50% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated dose to achieve 90% response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score (DAS28)-Part A</title>
        <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score (DAS28)-Part A</title>
          <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.818" spread="0.981"/>
                    <measurement group_id="O2" value="-1.308" spread="1.092"/>
                    <measurement group_id="O3" value="-1.565" spread="1.440"/>
                    <measurement group_id="O4" value="-1.671" spread="1.193"/>
                    <measurement group_id="O5" value="-1.686" spread="1.344"/>
                    <measurement group_id="O6" value="-1.940" spread="1.152"/>
                    <measurement group_id="O7" value="-0.619" spread="1.109"/>
                    <measurement group_id="O8" value="-1.310" spread="1.303"/>
                    <measurement group_id="O9" value="-1.571" spread="1.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 - Part B</title>
        <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 DAS28 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821(TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821(TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821(TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 - Part B</title>
          <description>DAS28 consisted of a composite score of the following variables: TJC28, SJC28, CRP, and PtGADA-VAS. DAS28 was calculated as: DAS28 − CRP =0.56(square root TJC28) + 0.28(square root SJC28) + 0.36(ln[CRP +1]) + 0.014(VAS) + 0.96. A negative change indicated an improvement.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 DAS28 results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.143" spread="1.177"/>
                    <measurement group_id="O2" value="-1.832" spread="1.031"/>
                    <measurement group_id="O3" value="-2.320" spread="1.292"/>
                    <measurement group_id="O4" value="-2.277" spread="1.337"/>
                    <measurement group_id="O5" value="-2.280" spread="1.316"/>
                    <measurement group_id="O6" value="-2.475" spread="1.140"/>
                    <measurement group_id="O7" value="-1.740" spread="1.460"/>
                    <measurement group_id="O8" value="-1.604" spread="1.282"/>
                    <measurement group_id="O9" value="-1.874" spread="1.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ACR20/50/70 Response - Part A</title>
        <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ACR20/50/70 Response - Part A</title>
          <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70%, respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="70.3"/>
                    <measurement group_id="O5" value="50.9"/>
                    <measurement group_id="O6" value="54.1"/>
                    <measurement group_id="O7" value="23.4"/>
                    <measurement group_id="O8" value="40.0"/>
                    <measurement group_id="O9" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="29.7"/>
                    <measurement group_id="O5" value="26.3"/>
                    <measurement group_id="O6" value="27.0"/>
                    <measurement group_id="O7" value="7.8"/>
                    <measurement group_id="O8" value="20.0"/>
                    <measurement group_id="O9" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="13.5"/>
                    <measurement group_id="O5" value="7.0"/>
                    <measurement group_id="O6" value="13.5"/>
                    <measurement group_id="O7" value="3.1"/>
                    <measurement group_id="O8" value="3.1"/>
                    <measurement group_id="O9" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-value is for ACR20-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <p_value_desc>P-value is for ACR50-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.388</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.696</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.112</p_value>
            <p_value_desc>P-value is for ACR70-NRI at Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With of ACR20/50/70 Response - Part B</title>
        <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100].</description>
        <time_frame>Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 ACR20/50/70 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821(TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With of ACR20/50/70 Response - Part B</title>
          <description>ACR20 (or ACR50 or ACR70) responders were participants with at least 20% (or 50% or 70% respectively) improvement from baseline TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. Missing values were imputed using NRI. Percentage of participants was calculated as: (number of ACR20 [or ACR50 or ACR70] responders per treatment arm) / (total number of participants per treatment arm) * 100].</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 ACR20/50/70 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="65.6"/>
                    <measurement group_id="O3" value="67.9"/>
                    <measurement group_id="O4" value="80.6"/>
                    <measurement group_id="O5" value="72.7"/>
                    <measurement group_id="O6" value="80.8"/>
                    <measurement group_id="O7" value="51.6"/>
                    <measurement group_id="O8" value="43.9"/>
                    <measurement group_id="O9" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="48.4"/>
                    <measurement group_id="O5" value="47.7"/>
                    <measurement group_id="O6" value="61.5"/>
                    <measurement group_id="O7" value="32.3"/>
                    <measurement group_id="O8" value="22.0"/>
                    <measurement group_id="O9" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="32.1"/>
                    <measurement group_id="O4" value="22.6"/>
                    <measurement group_id="O5" value="11.4"/>
                    <measurement group_id="O6" value="30.8"/>
                    <measurement group_id="O7" value="19.4"/>
                    <measurement group_id="O8" value="9.8"/>
                    <measurement group_id="O9" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A</title>
        <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 milligram (mg) LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part A</title>
          <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="5.20"/>
                    <measurement group_id="O2" value="-6.02" spread="7.35"/>
                    <measurement group_id="O3" value="-6.79" spread="7.67"/>
                    <measurement group_id="O4" value="-7.05" spread="6.28"/>
                    <measurement group_id="O5" value="-7.66" spread="8.96"/>
                    <measurement group_id="O6" value="-8.96" spread="7.47"/>
                    <measurement group_id="O7" value="-2.96" spread="6.31"/>
                    <measurement group_id="O8" value="-6.02" spread="7.31"/>
                    <measurement group_id="O9" value="-6.02" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B</title>
        <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 TJC results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821(TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-TJC - Part B</title>
          <description>TJC was determined by examination of 28 joint counts that were assessed for tenderness by pressure and joint manipulation on physical examination. The participant was asked for pain sensations on these manipulations and was watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-non-tender dichotomy. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, arthrodesed joints were identified by the investigator and excluded from evaluation during the study. Any joints that required intra-articular injections during the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of tender joints ranged from 0-28. A negative change indicated fewer tender joints.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 TJC results.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.73" spread="6.85"/>
                    <measurement group_id="O2" value="-8.78" spread="5.32"/>
                    <measurement group_id="O3" value="-11.43" spread="6.54"/>
                    <measurement group_id="O4" value="-9.55" spread="6.20"/>
                    <measurement group_id="O5" value="-10.86" spread="7.48"/>
                    <measurement group_id="O6" value="-10.55" spread="7.11"/>
                    <measurement group_id="O7" value="-6.62" spread="8.39"/>
                    <measurement group_id="O8" value="-7.35" spread="6.83"/>
                    <measurement group_id="O9" value="-6.81" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A</title>
        <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part A</title>
          <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints count ranged from 0-28. A negative change indicated fewer swollen joints.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="6.07"/>
                    <measurement group_id="O2" value="-4.25" spread="5.58"/>
                    <measurement group_id="O3" value="-6.51" spread="7.65"/>
                    <measurement group_id="O4" value="-6.16" spread="6.44"/>
                    <measurement group_id="O5" value="-7.49" spread="7.98"/>
                    <measurement group_id="O6" value="-6.52" spread="6.62"/>
                    <measurement group_id="O7" value="-1.69" spread="5.93"/>
                    <measurement group_id="O8" value="-5.57" spread="5.51"/>
                    <measurement group_id="O9" value="-5.15" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.093</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B</title>
        <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 SJC results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821(TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-SJC - Part B</title>
          <description>SJC was determined by examination of 28 joint that were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. Swelling secondary to osteoarthrosis was assessed as not swollen, unless there was unmistakable fluctuation. Joint assessments for each participant were performed by the same assessor, when possible, throughout the study to minimize variation. Replaced, ankylosed, or arthrodesed joints were identified by the investigator and were excluded from evaluation during the study. Any joints that required intra-articular injections over the course of the study were excluded from evaluation from the time of the injection to the conclusion of the study. The number of swollen joints ranged from 0-28. A negative change indicated fewer swollen joints.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 SJC results.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="6.15"/>
                    <measurement group_id="O2" value="-5.73" spread="4.95"/>
                    <measurement group_id="O3" value="-9.06" spread="5.92"/>
                    <measurement group_id="O4" value="-7.26" spread="5.73"/>
                    <measurement group_id="O5" value="-8.95" spread="6.64"/>
                    <measurement group_id="O6" value="-8.96" spread="6.06"/>
                    <measurement group_id="O7" value="-7.32" spread="6.45"/>
                    <measurement group_id="O8" value="-5.46" spread="6.51"/>
                    <measurement group_id="O9" value="-6.29" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A</title>
        <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain.&quot; The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-PAAP VAS - Part A</title>
          <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain.&quot; The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="23.7"/>
                    <measurement group_id="O2" value="-18.7" spread="22.8"/>
                    <measurement group_id="O3" value="-21.3" spread="28.4"/>
                    <measurement group_id="O4" value="-29.8" spread="24.1"/>
                    <measurement group_id="O5" value="-25.8" spread="23.0"/>
                    <measurement group_id="O6" value="-25.3" spread="27.5"/>
                    <measurement group_id="O7" value="-9.4" spread="24.0"/>
                    <measurement group_id="O8" value="-10.3" spread="24.7"/>
                    <measurement group_id="O9" value="-18.8" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.315</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B</title>
        <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain&quot;. The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PAAP-VAS results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set-PAAP-VAS - Part B</title>
          <description>Participants were asked to assess his/her current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as &quot;no pain&quot; and the right end (100 mm) marked &quot;worst possible pain&quot;. The scale was administered prior to the TJC and SJC count examinations. Results were expressed in mm measured between the left end of the scale and the crossing point of the vertical line of the tick. A negative change indicated a lessening of the participant's arthritis pain.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PAAP-VAS results.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="27.8"/>
                    <measurement group_id="O2" value="-26.2" spread="20.3"/>
                    <measurement group_id="O3" value="-33.3" spread="33.4"/>
                    <measurement group_id="O4" value="-36.2" spread="27.4"/>
                    <measurement group_id="O5" value="-32.4" spread="22.6"/>
                    <measurement group_id="O6" value="-41.2" spread="23.0"/>
                    <measurement group_id="O7" value="-25.5" spread="22.3"/>
                    <measurement group_id="O8" value="-16.5" spread="21.1"/>
                    <measurement group_id="O9" value="-26.2" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A</title>
        <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part A</title>
          <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="21.4"/>
                    <measurement group_id="O2" value="-17.3" spread="20.9"/>
                    <measurement group_id="O3" value="-18.5" spread="28.7"/>
                    <measurement group_id="O4" value="-29.1" spread="23.1"/>
                    <measurement group_id="O5" value="-22.1" spread="23.7"/>
                    <measurement group_id="O6" value="-30.1" spread="26.9"/>
                    <measurement group_id="O7" value="-10.1" spread="24.7"/>
                    <measurement group_id="O8" value="-12.1" spread="27.9"/>
                    <measurement group_id="O9" value="-21.6" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.778</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.865</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.331</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is for Week 12..</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B</title>
        <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PtGADA-VAS results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - PtGADA-VAS - Part B</title>
          <description>The participant was asked to give an overall assessment of his/her current arthritis disease activity. The participants response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; to the right end (100 mm) marked &quot;extremely active arthritis.&quot; A negative change indicated an improvement in the participant's assessment of disease activity.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PtGADA-VAS results.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.4" spread="26.2"/>
                    <measurement group_id="O2" value="-24.9" spread="25.4"/>
                    <measurement group_id="O3" value="-31.8" spread="30.4"/>
                    <measurement group_id="O4" value="-34.8" spread="27.0"/>
                    <measurement group_id="O5" value="-28.5" spread="24.7"/>
                    <measurement group_id="O6" value="-39.8" spread="25.5"/>
                    <measurement group_id="O7" value="-22.4" spread="23.2"/>
                    <measurement group_id="O8" value="-17.8" spread="21.4"/>
                    <measurement group_id="O9" value="-25.1" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A</title>
        <description>The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part A</title>
          <description>The investigator gave an overall assessment of the severity of the participants disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="19.0"/>
                    <measurement group_id="O2" value="-21.0" spread="15.6"/>
                    <measurement group_id="O3" value="-21.7" spread="25.2"/>
                    <measurement group_id="O4" value="-26.7" spread="18.1"/>
                    <measurement group_id="O5" value="-24.5" spread="22.3"/>
                    <measurement group_id="O6" value="-28.8" spread="24.2"/>
                    <measurement group_id="O7" value="-8.6" spread="21.4"/>
                    <measurement group_id="O8" value="-25.7" spread="22.2"/>
                    <measurement group_id="O9" value="-22.0" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B</title>
        <description>The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PhGA-VAS results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - PhGA-VAS - Part B</title>
          <description>The investigator gave an overall assessment of the severity of the participant's disease activity. The physician's response was recorded by marking a vertical tick on a 100-mm VAS with the left end (0 mm) marked as &quot;no arthritis activity&quot; and the right end (100 mm) marked as &quot;extremely active arthritis.&quot; A negative change indicated a lessening in the severity of the participant's disease activity.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 PhGA-VAS results.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.1" spread="21.7"/>
                    <measurement group_id="O2" value="-30.1" spread="22.0"/>
                    <measurement group_id="O3" value="-38.5" spread="28.4"/>
                    <measurement group_id="O4" value="-38.0" spread="18.5"/>
                    <measurement group_id="O5" value="-31.0" spread="20.7"/>
                    <measurement group_id="O6" value="-44.4" spread="17.7"/>
                    <measurement group_id="O7" value="-30.1" spread="22.5"/>
                    <measurement group_id="O8" value="-28.9" spread="25.8"/>
                    <measurement group_id="O9" value="-32.7" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A</title>
        <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part A</title>
          <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.575" spread="22.336"/>
                    <measurement group_id="O2" value="-6.079" spread="10.289"/>
                    <measurement group_id="O3" value="-9.435" spread="23.148"/>
                    <measurement group_id="O4" value="-7.999" spread="14.740"/>
                    <measurement group_id="O5" value="-11.968" spread="19.792"/>
                    <measurement group_id="O6" value="-13.575" spread="25.692"/>
                    <measurement group_id="O7" value="1.229" spread="14.811"/>
                    <measurement group_id="O8" value="-9.521" spread="20.312"/>
                    <measurement group_id="O9" value="-8.297" spread="21.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B</title>
        <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 CRP results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Individual Components of the ACR Core Set - CRP - Part B</title>
          <description>CRP is a biological marker of disease activity. A negative change indicated an improvement in participant's disease activity.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 CRP results.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.548" spread="18.555"/>
                    <measurement group_id="O2" value="-4.556" spread="12.937"/>
                    <measurement group_id="O3" value="-11.340" spread="23.347"/>
                    <measurement group_id="O4" value="-7.865" spread="22.607"/>
                    <measurement group_id="O5" value="-14.519" spread="19.260"/>
                    <measurement group_id="O6" value="-6.860" spread="16.745"/>
                    <measurement group_id="O7" value="-12.094" spread="28.917"/>
                    <measurement group_id="O8" value="-10.130" spread="18.030"/>
                    <measurement group_id="O9" value="-9.004" spread="19.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A</title>
        <description>Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population])</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in European League Against Rheumatism Responder Index (EULAR) 28 - Part A</title>
          <description>Assessment of participant's rheumatoid arthritis (RA) by the EULAR that is based on the DAS 28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="67.5"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="75.7"/>
                    <measurement group_id="O5" value="73.2"/>
                    <measurement group_id="O6" value="75.7"/>
                    <measurement group_id="O7" value="36.5"/>
                    <measurement group_id="O8" value="60.0"/>
                    <measurement group_id="O9" value="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is for Week 12 LOCF.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>P-value is for Week 12 LOCF.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for Week 12 LOCF.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is for Week 12 LOCF.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is for Week 12 LOCF.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in EULAR28 - Part B</title>
        <description>Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
        <time_frame>Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 EULAR28 results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in EULAR28 - Part B</title>
          <description>Assessment of participant's RA by the EULAR that is based on the DAS28 joint count. Participants were categorized as non-responders or responders (moderate responders + good responders). Percentage of participants was calculated as: (number of responders / number of participants) * 100.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 EULAR28 results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2"/>
                    <measurement group_id="O2" value="81.8"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="83.9"/>
                    <measurement group_id="O5" value="84.1"/>
                    <measurement group_id="O6" value="88.5"/>
                    <measurement group_id="O7" value="64.5"/>
                    <measurement group_id="O8" value="73.2"/>
                    <measurement group_id="O9" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR-N - Part A</title>
        <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value) / baseline value] * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug with results at Week 12; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR-N - Part A</title>
          <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value) / baseline value] * 100.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug with results at Week 12; LOCF.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="56"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.034" spread="104.809"/>
                    <measurement group_id="O2" value="-0.699" spread="139786"/>
                    <measurement group_id="O3" value="15.162" spread="51.130"/>
                    <measurement group_id="O4" value="11.137" spread="128.516"/>
                    <measurement group_id="O5" value="18.351" spread="41.493"/>
                    <measurement group_id="O6" value="23.375" spread="42.173"/>
                    <measurement group_id="O7" value="-7.356" spread="45.724"/>
                    <measurement group_id="O8" value="2.264" spread="59.277"/>
                    <measurement group_id="O9" value="11.541" spread="49.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR-N - Part B</title>
        <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value)/baseline value] * 100.</description>
        <time_frame>Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 ACR-N results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR-N - Part B</title>
          <description>ACR-N was a continuous measure of clinical, laboratory and functional outcomes in RA that characterized the percentage of improvement in RA disease activity from baseline. The index was defined as the lowest of either: the percent change in TJC, the percent change in SJC, or the median percent change of the remaining 5 ACR core criteria: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, and PhGA-VAS. For each criterion, percent change was calculated as: [(post baseline value - baseline value)/baseline value] * 100.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 ACR-N results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.839" spread="42.241"/>
                    <measurement group_id="O2" value="33.154" spread="32.439"/>
                    <measurement group_id="O3" value="39.922" spread="37.930"/>
                    <measurement group_id="O4" value="34.847" spread="69.410"/>
                    <measurement group_id="O5" value="38.996" spread="30.715"/>
                    <measurement group_id="O6" value="49.152" spread="31.544"/>
                    <measurement group_id="O7" value="22.230" spread="54.682"/>
                    <measurement group_id="O8" value="14.389" spread="45.461"/>
                    <measurement group_id="O9" value="30.891" spread="41.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A</title>
        <description>The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: defined as all data from all randomized participants who received at least 1 dose of study drug LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale - Part A</title>
          <description>The FACIT Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
          <population>Part A FAS: defined as all data from all randomized participants who received at least 1 dose of study drug LOCF.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.566" spread="9.168"/>
                    <measurement group_id="O2" value="5.725" spread="8.706"/>
                    <measurement group_id="O3" value="6.057" spread="13.512"/>
                    <measurement group_id="O4" value="8.924" spread="9.469"/>
                    <measurement group_id="O5" value="7.250" spread="9.245"/>
                    <measurement group_id="O6" value="5.838" spread="7.946"/>
                    <measurement group_id="O7" value="4.953" spread="9.152"/>
                    <measurement group_id="O8" value="4.400" spread="8.068"/>
                    <measurement group_id="O9" value="6.627" spread="8.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.962</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.316</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.975</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACIT Fatigue Scale - Part B</title>
        <description>The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 FACIT results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACIT Fatigue Scale - Part B</title>
          <description>The FACIT-Fatigue Scale was a brief participant-reported questionnaire measure of fatigue and consisted of 13 items that assessed tiredness, weakness and difficulty conducting usual activities due to fatigue. Each question was scored on a 5-point scale from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue. For missing data, scores were prorated using the average of the other answers in the scales as long as more than 50% of the items were answered. A negative change indicated less fatigue.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 FACIT results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.390" spread="8.405"/>
                    <measurement group_id="O2" value="4.879" spread="10.810"/>
                    <measurement group_id="O3" value="8.500" spread="12.880"/>
                    <measurement group_id="O4" value="9.177" spread="11.637"/>
                    <measurement group_id="O5" value="7.295" spread="10.436"/>
                    <measurement group_id="O6" value="6.038" spread="9.986"/>
                    <measurement group_id="O7" value="8.323" spread="9.304"/>
                    <measurement group_id="O8" value="4.341" spread="8.493"/>
                    <measurement group_id="O9" value="6.647" spread="9.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A</title>
        <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part A</title>
          <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="123.7"/>
                    <measurement group_id="O2" value="-24.3" spread="87.3"/>
                    <measurement group_id="O3" value="-52.7" spread="142.0"/>
                    <measurement group_id="O4" value="-71.4" spread="143.9"/>
                    <measurement group_id="O5" value="-63.0" spread="57.0"/>
                    <measurement group_id="O6" value="-69.0" spread="64.1"/>
                    <measurement group_id="O7" value="-36.3" spread="137.7"/>
                    <measurement group_id="O8" value="-62.0" spread="138.1"/>
                    <measurement group_id="O9" value="-43.1" spread="116.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.982</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.276</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA adjusted for treatment and baseline value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B</title>
        <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 Duration of Morning Stiffness results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821(bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duration of Morning Stiffness (Minutes) - Part B</title>
          <description>The investigator queried the participants about the duration of morning stiffness in and around their joints and the results (in minutes) were recorded by the investigator. Duration was the time from when the participants woke up to when normal activities could be resumed. Durations recorded as longer than 12 hours (720 minutes) were summarized as 720 minutes. An increase in duration from baseline indicated a joint worsening and a decrease from baseline indicated joint improvement.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 Duration of Morning Stiffness results.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.1" spread="111.3"/>
                    <measurement group_id="O2" value="-70.2" spread="112.3"/>
                    <measurement group_id="O3" value="-55.6" spread="72.9"/>
                    <measurement group_id="O4" value="-92.3" spread="136.7"/>
                    <measurement group_id="O5" value="-68.8" spread="72.5"/>
                    <measurement group_id="O6" value="-82.3" spread="79.2"/>
                    <measurement group_id="O7" value="-61.3" spread="161.9"/>
                    <measurement group_id="O8" value="-60.9" spread="164.7"/>
                    <measurement group_id="O9" value="-85.9" spread="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI - Part A</title>
        <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.</description>
        <time_frame>Baseline, up to Week 12</time_frame>
        <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI - Part A</title>
          <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range of 0 to 3. Negative mean changes from baseline indicated improvement.</description>
          <population>Part A FAS: All randomized participants who received at least 1 dose of study drug; LOCF.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.220" spread="0.459"/>
                    <measurement group_id="O2" value="-0.322" spread="0.493"/>
                    <measurement group_id="O3" value="-0.418" spread="0.693"/>
                    <measurement group_id="O4" value="-0.537" spread="0.639"/>
                    <measurement group_id="O5" value="-0.469" spread="0.517"/>
                    <measurement group_id="O6" value="-0.476" spread="0.655"/>
                    <measurement group_id="O7" value="-0.182" spread="0.458"/>
                    <measurement group_id="O8" value="-0.223" spread="0.448"/>
                    <measurement group_id="O9" value="-0.265" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.515</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.393</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>P-value is for Week 12.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI - Part B</title>
        <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.</description>
        <time_frame>Baseline, Week 64</time_frame>
        <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 HAQ-DI results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg/160 mg LY2439821 (bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg/160 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI - Part B</title>
          <description>HAQ-DI was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ-DI score. If the participant had scores for fewer than 6 categories, the HAQ-DI score was considered missing. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.</description>
          <population>All participants from Part A who entered the open-label portion of the study, Part B, with Week 64 HAQ-DI results.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.616" spread="0.609"/>
                    <measurement group_id="O2" value="-0.542" spread="0.611"/>
                    <measurement group_id="O3" value="-0.665" spread="0.662"/>
                    <measurement group_id="O4" value="-0.673" spread="0.705"/>
                    <measurement group_id="O5" value="-0.554" spread="0.614"/>
                    <measurement group_id="O6" value="-0.697" spread="0.571"/>
                    <measurement group_id="O7" value="-0.331" spread="0.449"/>
                    <measurement group_id="O8" value="-0.250" spread="0.460"/>
                    <measurement group_id="O9" value="-0.309" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Exposure and Response of Individual Components of the ACR Core Set</title>
        <time_frame>Through Week 72</time_frame>
        <population>Relationship between exposure and response in Individual Components (IC) of ACR Core Set analysis was reported in outcome measures (OMs) 10-21 as change from baseline in IC of ACR Core Sets: TJC, SJC, PAAP-VAS, PtGADA-VAS, PhGA-VAS, and CRP (Parts A and B). No further analyses were completed for individual components of ACR Core Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Exposure and Response of Individual Components of the ACR Core Set</title>
          <population>Relationship between exposure and response in Individual Components (IC) of ACR Core Set analysis was reported in outcome measures (OMs) 10-21 as change from baseline in IC of ACR Core Sets: TJC, SJC, PAAP-VAS, PtGADA-VAS, PhGA-VAS, and CRP (Parts A and B). No further analyses were completed for individual components of ACR Core Set.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Exposure and Response of ACR20/50/70/N</title>
        <time_frame>Through Week 72</time_frame>
        <population>Relationship between exposure and response ACR20/50/70/N analysis was reported in OMs 8 and 9, as percentage of participants with ACR 20/50/70 Response (Parts A and B) and OMs 24 and 25 as percentage of participants with ACR-N (Parts A and B) respectively. No further analyses were completed for ACR20/50/70/N.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Exposure and Response of ACR20/50/70/N</title>
          <population>Relationship between exposure and response ACR20/50/70/N analysis was reported in OMs 8 and 9, as percentage of participants with ACR 20/50/70 Response (Parts A and B) and OMs 24 and 25 as percentage of participants with ACR-N (Parts A and B) respectively. No further analyses were completed for ACR20/50/70/N.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Exposure and Response of DAS28</title>
        <time_frame>Through Week 72</time_frame>
        <population>Relationship between exposure and response of DAS28 analysis was reported in OMs 6 and 7 as change from baseline in DAS28 (Parts A and B) respectively. No further analyses were completed for DAS28.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Exposure and Response of DAS28</title>
          <population>Relationship between exposure and response of DAS28 analysis was reported in OMs 6 and 7 as change from baseline in DAS28 (Parts A and B) respectively. No further analyses were completed for DAS28.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Exposure and Response of EULAR28</title>
        <time_frame>Through Week 72</time_frame>
        <population>Relationship between exposure and response of EULAR 28 analysis was reported in OMs 22 and 23 as percentage of participants in EULAR28 (Parts A and B), respectively. No further analyses were completed for EULAR28.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Exposure and Response of EULAR28</title>
          <population>Relationship between exposure and response of EULAR 28 analysis was reported in OMs 22 and 23 as percentage of participants in EULAR28 (Parts A and B), respectively. No further analyses were completed for EULAR28.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State</title>
        <description>Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).</description>
        <time_frame>Predose: Day 0, Day 1 or 2 or 3, Day 7, Weeks 6, 10, 16, 40 and 64 and Postdose: Day 0 and Week 6</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug in Part A and had estimable PK data, as well as, participants from Part A who entered the open-label portion of the study, Part B, and had estimable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A.</description>
          </group>
          <group group_id="O8">
            <title>Part B: 160 mg LY2439821 (bDMARD-naive and TNFα-IR Population)</title>
            <description>160 mg LY2439821 administered subcutaneously at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60, in Part B.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2439821 at Steady State</title>
          <description>Evaluable PK concentrations from all time points, including data from placebo participants who elected active treatment in Part B, were combined and utilized in a population approach to determine the population median estimates and 90% confidence intervals at steady state. Day 0 and Week 6 postdose samples were collected as late as possible during the dosing visit (in other words, the postdose samples were collected at the end of their respective visits).</description>
          <population>All randomized participants who received at least 1 dose of study drug in Part A and had estimable PK data, as well as, participants from Part A who entered the open-label portion of the study, Part B, and had estimable PK data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" lower_limit="138" upper_limit="783"/>
                    <measurement group_id="O2" value="1060" lower_limit="352" upper_limit="2580"/>
                    <measurement group_id="O3" value="3230" lower_limit="1140" upper_limit="7970"/>
                    <measurement group_id="O4" value="7580" lower_limit="2590" upper_limit="18600"/>
                    <measurement group_id="O5" value="17100" lower_limit="6870" upper_limit="42000"/>
                    <measurement group_id="O6" value="7320" lower_limit="2740" upper_limit="17700"/>
                    <measurement group_id="O7" value="16200" lower_limit="6040" upper_limit="40600"/>
                    <measurement group_id="O8" value="18600" lower_limit="8040" upper_limit="45000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-LY2439821 Antibodies</title>
        <description>Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.</description>
        <time_frame>Week 16, Week 64</time_frame>
        <population>Part A (Week 16) FAS: all randomized participants who received at least 1 dose of study drug with antibody testing performed; Part B (Week 64): All participants from Part A who entered the open-label portion of the study, part B, with baseline and at least 1 post-baseline antibody testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (bDMARD-naive Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O2">
            <title>3 mg LY2439821 (bDMARD-naive Population)</title>
            <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY2439821 (bDMARD-naive Population)</title>
            <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O4">
            <title>30 mg LY2439821 (bDMARD-naive Population)</title>
            <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O5">
            <title>80 mg LY2439821 (bDMARD-naive Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O6">
            <title>180 mg LY2439821(bDMARD-naive Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O7">
            <title>Placebo (TNFα-IR Population)</title>
            <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O8">
            <title>80 mg LY2439821 (TNFα-IR Population)</title>
            <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
          <group group_id="O9">
            <title>180 mg LY2439821 (TNFα-IR Population)</title>
            <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-LY2439821 Antibodies</title>
          <description>Treatment-emergent anti-LY2439821 antibody positive participants were defined as a titer change from baseline that was at least 2 dilutions (4-fold) increase. Participants must have had an assessment to be classified as treatment emergent antibody positive or negative.</description>
          <population>Part A (Week 16) FAS: all randomized participants who received at least 1 dose of study drug with antibody testing performed; Part B (Week 64): All participants from Part A who entered the open-label portion of the study, part B, with baseline and at least 1 post-baseline antibody testing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part A Week 16 (n=43,35,34,35,49,33,52,57,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="8.6"/>
                    <measurement group_id="O5" value="16.3"/>
                    <measurement group_id="O6" value="15.2"/>
                    <measurement group_id="O7" value="7.7"/>
                    <measurement group_id="O8" value="10.5"/>
                    <measurement group_id="O9" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B Week 64 (n=37,32,28,30,40,26,31,41,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.5"/>
                    <measurement group_id="O6" value="3.8"/>
                    <measurement group_id="O7" value="6.5"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3 mg LY2439821 (bDMARD-naive Population) Part A</title>
          <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E2">
          <title>10 mg LY2439821 (bDMARD-naive Population) Part A</title>
          <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E3">
          <title>30 mg LY2439821 (bDMARD-naive Population) Part A</title>
          <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E4">
          <title>80 mg LY2439821 (bDMARD-naive Population) Part A</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E5">
          <title>180 mg LY2439821(bDMARD-naive Population) Part A</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E6">
          <title>Placebo (bDMARD-naive Population) Part A</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E7">
          <title>80 mg LY2439821 (TNFa-IR Population) Part A</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E8">
          <title>180 mg LY2439821 (TNFa-IR Population) Part A</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E9">
          <title>Placebo (TNFa-IR Population) Part A</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E10">
          <title>3 mg/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>3 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E11">
          <title>10 mg/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>10 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E12">
          <title>30 mg/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>30 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E13">
          <title>80 mg/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E14">
          <title>180 mg/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E15">
          <title>Placebo/160 mg LY2439821 (bDMARD-naive Population) Part B</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E16">
          <title>80 mg/160 mg LY2439821 (TNFa-IR Population) Part B</title>
          <description>80 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E17">
          <title>180 mg/160 mg LY2439821 (TNFa-IR Population) Part B</title>
          <description>180 mg LY2439821 administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
        <group group_id="E18">
          <title>Placebo/160 mg LY2439821 (TNFa-IR Population) Part B</title>
          <description>Placebo administered subcutaneously at Weeks 0, 1, 2, 4, 6, 8 and 10 in Part A, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Serum sickness-like reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Whipple's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E11" subjects_affected="19" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E13" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E14" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E15" subjects_affected="26" subjects_at_risk="46"/>
                <counts group_id="E16" subjects_affected="23" subjects_at_risk="57"/>
                <counts group_id="E17" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E18" subjects_affected="23" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="6" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="13" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="8" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E17" events="7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E18" events="7" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E10" events="6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="14" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="22" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="8" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E12" events="6" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E15" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E16" events="9" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E18" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E18" events="3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E14" events="5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

